Shots:
- Boehringer Ingelheim has signed an agreement with Quallent Pharmaceuticals to expand the access of citrate-free adalimumab-adbm, a biosimilar to Humira (adalimumab), across the US
- As per the agreement, BI will handle the manufacturing activity of adalimumab-adbm for Quallent and will continue the commercialization of Cyltezo (adalimumab-adbm) injection and Adalimumab-adbm
- Quallent will provide high-concentration (40mg/0.4mL) and low-concentration (40mg/0.8mL) citrate-free adalimumab-adbm in a pre-filled syringe or pen. Furthermore, Quallent’s 40mg/0.8mL private-labeled adalimumab-adbm will share Adalimumab-adbm’s interchangeability designation
Ref: Boehringer Ingelheim | Image: Boehringer Ingelheim | Press Release
Related News:- Xbrane Biopharma and STADA Team Up with Valorum Biologics for Commercializing Xlucane (Biosimilar, Ranibizumab) Across the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
